

# HYBRID PROTOCOL. ACCELERATED SUCCESS.

## An Adaptive Design FIH Immunology Study

A small European biotechnology client approached Covance seeking the most efficient FIH adaptive trial design for an immunology drug study. Covance had already provided preclinical research on this molecule, so we had insight into the likely safety profile. Covance suggested a hybrid protocol – initially assessing the molecule in healthy volunteers, then evaluating results in patients – enabling the sponsor to include early efficacy data in the study. This approach would not only save time and money but also add significant value to the asset, as potential licensing partners could see data demonstrating both effectiveness and safety.

### Understanding the Challenge

- ▶ Adaptive trial optimising the ongoing study design
- ▶ Support for early “go/no-go” decision-making
- ▶ Continuity from preclinical to FIH clinical phases
- ▶ Hybrid protocol design, recruiting both healthy volunteers and patients

### Hybrid, Adaptive Protocol Accelerates “Go” Decision

Covance Early Phase Development Solutions (EPDS) offers the advantage of fast information flow between preclinical and clinical teams. For this client, a streamlined protocol design process allowed finalised protocol within days of toxicology reports being available. The combined EPDS and clinical pharmacology team leveraged Covance late-stage clinical expertise, suggesting the inclusion of a small patient group in the FIH study to provide early proof of principal in this case. The approach was both practical and feasible, saving the time and expense of a separate study.

**A hybrid protocol offers faster “go/no-go” decision-making for further development. If a molecule is safe, well tolerated plus effective, there is a strong “go” signal for success. Accelerated decision-making saves time and money while enhancing opportunity.**

The Covance Leeds CRU conducted the healthy volunteer arm of the study, recruiting 48 volunteers in three months. The process included five dose-escalation steps, with up to two weeks between dose-escalation steps required to ensure sufficient decision-making data for this new biological entity. Along with safety, tolerability and PK evaluations following IV dosing, the team assessed subcutaneous administration, as this is the target dose route for subsequent clinical studies. With the use of optimised processes to access blinded interim data, the process enabled a rapid start to the patient portion of the study.

To ensure robust patient recruitment, the team developed a network of four recruitment sites: the Covance Leeds CRU plus dedicated, experienced Clinical Pharmacology Units in three UK-based hospitals – including the Royal Liverpool Hospital CRU. Among the 12 patients recruited within four months, efficacy signals were dramatic, delivering a strong “go” signal for development success.

This continuity of preclinical research to the FIH study – including early proof of principal – further streamlines the next phase of development. The data generated have enabled a more efficient design and earlier initiation of a Phase II study. Our experts’ understanding of this molecule and its development provides time and knowledge advantages to the client.

Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

The Americas + 1.888.COVANCE (+1.888.268.2623) + 1.609.452.4440  
Europe / Africa + 00.800.2682.2682 +44.1423.500888  
Asia Pacific + 800.6568.3000 +65.6.5686588

© 2017 Covance Inc.

CSCDS093-0117

**COVANCE**  
SOLUTIONS MADE REAL®